Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Salim Virani and Khurram Nasir.
Salim Virani
Connection Strength
4.544
Khurram Nasir
  1. PCSK9 Inhibitors Prior Authorization. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005910.
    View in: PubMed
    Score: 0.834
  2. Determinants of Influenza Vaccine Uptake in Patients With Cardiovascular Disease and Strategies for Improvement. J Am Heart Assoc. 2021 08 03; 10(15):e019671.
    View in: PubMed
    Score: 0.240
  3. Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. Am J Prev Cardiol. 2021 Mar; 5:100150.
    View in: PubMed
    Score: 0.231
  4. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.201
  5. Is diabetes mellitus equivalent to atherosclerotic cardiovascular disease from a healthcare cost perspective? Insights from the Medical Expenditure Panel Survey: 2010-2013. Cardiovasc Endocrinol Metab. 2018 Sep; 7(3):64-67.
    View in: PubMed
    Score: 0.195
  6. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.194
  7. Life's Simple 7 and the risk of atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2018 08; 275:174-181.
    View in: PubMed
    Score: 0.193
  8. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
    View in: PubMed
    Score: 0.190
  9. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. J Am Heart Assoc. 2018 01 22; 7(2).
    View in: PubMed
    Score: 0.188
  10. Persistent socioeconomic disparities in cardiovascular risk factors and health in the United States: Medical Expenditure Panel Survey 2002-2013. Atherosclerosis. 2018 02; 269:301-305.
    View in: PubMed
    Score: 0.186
  11. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol. 2017 12 01; 2(12):1369-1374.
    View in: PubMed
    Score: 0.186
  12. Burden of Catastrophic Health Expenditures for Acute Myocardial Infarction and Stroke Among Uninsured in the United States. Circulation. 2018 01 23; 137(4):408-410.
    View in: PubMed
    Score: 0.185
  13. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.184
  14. Life's Simple 7 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2017 Jun 27; 6(6).
    View in: PubMed
    Score: 0.181
  15. Association Between Modifiable Risk Factors and Pharmaceutical Expenditures Among Adults With Atherosclerotic Cardiovascular Disease in the United States: 2012-2013 Medical Expenditures Panel Survey. J Am Heart Assoc. 2017 Jun 09; 6(6).
    View in: PubMed
    Score: 0.180
  16. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.179
  17. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 04 01; 2(4):361-369.
    View in: PubMed
    Score: 0.178
  18. Patient-Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States: Medical Expenditure Panel Survey 2010 to 2013. Circ Cardiovasc Qual Outcomes. 2017 04; 10(4).
    View in: PubMed
    Score: 0.178
  19. Favorable cardiovascular risk factor profile is associated with lower healthcare expenditure and resource utilization among adults with diabetes mellitus free of established cardiovascular disease: 2012 Medical Expenditure Panel Survey (MEPS). Atherosclerosis. 2017 03; 258:79-83.
    View in: PubMed
    Score: 0.176
  20. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.126
  21. Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications. Am J Med. 2019 01; 132(1):61-70.e1.
    View in: PubMed
    Score: 0.049
  22. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 03 20; 137(12):e67-e492.
    View in: PubMed
    Score: 0.047
  23. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 03 07; 135(10):e146-e603.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.